Search

Displaying results 4511 - 4520 of 7059 in total
  1. Drug

    Glatiramer

    go.drugbank.com/drugs/DB05259
    ApprovedInvestigational

    [A248880] It was approved by the FDA in 1996, and a generic version became available in 2017. … [A248870] Originally, glatiramer acetate was designed as a stimulant of myelin basic protein (MBP), a myelin antigen involved in the development of multiple sclerosis (MS), to induce experimental autoimmune

    Synonyms: (T,G)-A-L
  2. Drug

    Renadirsen

    go.drugbank.com/drugs/DB19132
    Investigational

    Renadirsen is under investigation in clinical trial NCT04433234 (Long-term, Extension Study of Ds-5141b in Patients With Duchenne Muscular Dystrophy).

  3. Drug

    Remetinostat

    go.drugbank.com/drugs/DB14869
    Investigational

    Remetinostat is under investigation in clinical trial NCT02213861 (Efficacy, Safety and Tolerability Study of SHAPE in IA, IB or IIA Cutaneous T-cell Lymphoma).

  4. Drug

    MGN-4893

    go.drugbank.com/drugs/DB17338
    Experimental

    In February 2011, it was granted FDA orphan designation for the treatment of polycythemia vera.[L47356]

  5. Drug

    Valiltramiprosate

    go.drugbank.com/drugs/DB19191
    Investigational

    Valiltramiprosate is under investigation in clinical trial NCT06304883 (Long-term Extension of Phase 3 Study of ALZ- 801 in APOE4/4 Early AD Subjects).

  6. Drug

    Anisomycin

    go.drugbank.com/drugs/DB07374
    Experimental

    This drug acts to inhibit bacterial protein and DNA synthesis.

  7. Drug

    Tulisokibart

    go.drugbank.com/drugs/DB18719
    Investigational

    PRA023 is a humanized monoclonal antibody directed to vascular endothelial growth inhibitor, also known as tumour necrosis factor (TNF)-like ligand 1A (TL1A) and TNF superfamily member 15.

  8. Drug

    Idraparinux

    go.drugbank.com/drugs/DB06406
    Investigational

    As a result, Sanofi stopped the development of the drug. … Idraparinux, a synthetic pentasaccharide is an antithrombin-dependent inhibitor of activated factor X. It was developed for the treatment and prevention of thromboembolic events.

    Categories: Factor Xa Inhibitors
  9. Drug

    PSN9301

    go.drugbank.com/drugs/DB05001
    Experimental

    PSN9301 is an oral small molecule inhibitor of Dipeptidyl Peptidase IV (DP-IV), being developed for the treatment of type 2 diabetes. … PSN9301 has a very rapid onset and a relatively short duration of action, and available pre-clinical and clinical data indicate that it may be an ideal product candidate for meal-related dosing.

  10. Drug

    TAS-102

    go.drugbank.com/drugs/DB08937
    Investigational

    Trifluridine inhibits tumor growth by being incorporated into DNA during DNA synthesis. Tipiracil prevents trifluridine from being broken down when taken orally.